isomethyleugenol has been researched along with Acute Biphenotypic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Ge, M; Kang, T; Li, D; Liu, H; Wang, R; Wang, W; Xie, S; Xu, Q | 1 |
| Armstrong, SA; Bernt, KM; Chesworth, R; Copeland, RA; Daigle, SR; Jin, L; Johnston, LD; Kung, AL; Kuntz, KW; Majer, CR; Moyer, MP; Olhava, EJ; Pollock, RM; Richon, VM; Scott, MP; Smith, JJ; Sneeringer, CJ; Song, J; Therkelsen, CA; Tseng, JC; Xiao, Y | 1 |
2 other study(ies) available for isomethyleugenol and Acute Biphenotypic Leukemia
| Article | Year |
|---|---|
Deubiquitinating enzyme inhibitor alleviates cyclin A1-mediated proteasome inhibitor tolerance in mixed-lineage leukemia.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Chromatin; Cyclin A1; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Drug Tolerance; Gene Expression Regulation, Neoplastic; Histones; Humans; Leukemia, Biphenotypic, Acute; Methylation; Myeloid-Lymphoid Leukemia Protein; Prognosis; Proteasome Inhibitors; Ubiquitination | 2021 |
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Topics: Animals; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Rearrangement; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Leukemia, Biphenotypic, Acute; Lysine; Methylation; Methyltransferases; Mice; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2011 |